Company Active PLC

Company profile

Destiny Pharma PLC

Destiny Pharma | World-leading infection prevention.

World-leading infection prevention.

CRN
03167025
Founded
1996
Age
30

Overview

Legal name
DESTINY PHARMA LIMITED
Region
London
Registered address
C/O CORK GULLY LLP, 40
VILLIERS STREET
LONDON
WC2N 6NJ
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Destiny Pharma PLC
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

15 events
30 Sep
2025

Accounts due

Accounts Due

Next accounts due date

22 Dec
2024

Confirmation statement due

Confirmation Due

Next confirmation statement due date

08 Nov
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQ0MjQ5Mjc3NmFkaXF6a2N4

Published 08 Nov 2024 04:03

05 Nov
2024

Liquidation In Administration Result Creditors Meeting

Insolvency

AM07 | Transaction MzQ0MTI2NzIzNmFkaXF6a2N4 | Paper/PDF filed

Published 06 Nov 2024 07:22

19 Oct
2024

Liquidation In Administration Statement Of Affairs With Form Attached

Insolvency

AM02 | Transaction MzQzOTE0MzE1M2FkaXF6a2N4 | Paper/PDF filed

Published 20 Oct 2024 06:13

19 Oct
2024

Liquidation In Administration Proposals

Insolvency

AM03 | Transaction MzQzOTE4NDQ3MWFkaXF6a2N4 | Paper/PDF filed

Published 20 Oct 2024 06:11

03 Sep
2024

Resolution

Resolution

RESOLUTIONS | Transaction QURBTTVTVVphZGlxemtjeA | Paper/PDF filed

Published 05 Sep 2024 06:33

03 Sep
2024

Certificate Re Registration Public Limited Company To Private

Change-of-name

CERT10 | Transaction MzQzNDI5NTYzN2FkaXF6a2N4 | Paper/PDF filed

Published 05 Sep 2024 06:19

03 Sep
2024

Re Registration Memorandum Articles

Incorporation

MAR | Transaction MzQzNDI5NTYzNmFkaXF6a2N4 | Paper/PDF filed

Published 05 Sep 2024 06:14

03 Sep
2024

Reregistration Public To Private Company

Change-of-name

RR02 | Transaction MzQzNDI5NTM0MmFkaXF6a2N4 | Paper/PDF filed

Published 05 Sep 2024 06:09

30 Aug
2024

Liquidation In Administration Appointment Of Administrator

Insolvency

AM01 | Transaction MzQzMzEyNDAxMGFkaXF6a2N4 | Paper/PDF filed

Published 03 Sep 2024 07:02

30 Aug
2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQzMzEyNDI0OWFkaXF6a2N4 | Paper/PDF filed

Published 31 Aug 2024 07:00

31 Dec
2023

Accounts filed

Accounts

Last accounts made up date

08 Dec
2023

Confirmation statement filed

Confirmation

Last confirmation statement made up date

04 Mar
1996

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2019
Funded years
2019, 2020
Age at first award
22 years

Projects

2020 Collaborative R&D

SPOR-COV: Prophylaxis of COVID-19 using Innate Immunity

1 Sep 2020 to 31 Oct 2022

Awarded
£220,683
Total cost £315,900

The COVID-19 pandemic demonstrates the need for a rapid response to a global public health emergency. Vaccination is ideal but, as is now apparent, a vaccine for an unknown disease cannot be produced in time to avert a major socio-economic disaster. Alternative strategies have been considered but so far have received little attention. One of these is that...

2019 Collaborative R&D Lead participant

Evaluation of the Novel XF Drugs as Bacterial Resistance Breakers

1 Jan 2019 to 31 Aug 2022

Awarded
£362,389
Total cost £517,707

There is an urgent need for new drugs to treat infections resulting from bacteria that are now resistant to many of the current marketed antibiotics. This is a global issue encountered in low and middle-income countries (LMICs) where healthcare provisions may be less prevalent and so the impact is even greater. The jointly funded UK Department of Health a...

Product types

Collaborative R&D